T. Zabelina

发表

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

N. Kröger, A. Zander, T. Binder, 2011, Leukemia.

Low Number of Donor Activating Killer Immunoglobulin-Like Receptors (KIR) Genes but not KIR-Ligand Mismatch Prevents Relapse and Improves Disease-Free Survival in Leukemia Patients After In Vivo T-Cell Depleted Unrelated Stem Cell Transplantation

N. Kröger, A. Zander, T. Binder, 2006, Transplantation.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria

N. Kröger, A. Zander, F. Ayuk, 2015, Annals of Hematology.

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation

N. Kröger, A. Zander, F. Ayuk, 2014, Annals of Hematology.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis

N. Kröger, G. Wulf, D. Wolf, 2014, Leukemia.

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

N. Kröger, A. Zander, A. Reiter, 2007, Blood.

Allogeneic Stem Cell Transplantation for patients with lower risk MDS.

N. Kröger, F. Ayuk, C. Wolschke, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis

N. Kröger, R. Brand, M. Robin, 2011, Haematologica.

Short running title: allo SCT for MDS with bone marrow fibrosis

N. Kröger, R. Brand, M. Robin, 2010 .

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients

N. Kröger, A. Zander, U. Bacher, 2010, Advances in hematology.

Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.

N. Kröger, A. Zander, B. Fehse, 2001, Journal of hematotherapy & stem cell research.

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation

N. Kröger, D. Atanackovic, A. Zander, 2008, Haematologica.

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting.

N. Kröger, B. Fehse, K. Riecken, 2021, Blood advances.

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.

N. Kröger, A. Zander, B. Fehse, 2002, Blood.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.

N. Kröger, A. Zander, T. Binder, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.

J. Panse, N. Kröger, A. Zander, 2008, Experimental hematology.

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma

N. Kröger, A. Nagler, A. Zander, 2004, Leukemia.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

H. Einsele, N. Kröger, A. Zander, 2009, Blood.

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow

N. Kröger, S. Bielack, A. Zander, 1999, Bone Marrow Transplantation.

Risk models predicting survival after reduced‐intensity transplantation for myelofibrosis

N. Kröger, A. Zander, E. Holler, 2012, British journal of haematology.

Impact of molecular residual disease post allografting in myelofibrosis patients

N. Kröger, B. Fehse, A. Zander, 2017, Bone Marrow Transplantation.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation

T. Brümmendorf, N. Kröger, A. Zander, 2009, Leukemia & lymphoma.

Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents

E. Thiel, C. Junghanss, W. Heinz, 2011, Haematologica.

Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation

N. Kröger, A. Zander, F. Ayuk, 2010, Leukemia & lymphoma.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings

N. Kröger, M. Robin, J. Finke, 2013, Leukemia.

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.

N. Kröger, G. Kobbe, R. Kelsch, 2018, Biology of Blood and Marrow Transplantation.

Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients

N. Kröger, A. Zander, W. Krüger, 2001, Bone Marrow Transplantation.

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

N. Kröger, A. Zander, A. Nagler, 2005, Leukemia.

Outcome of allo-SCT for chronic myelomonocytic leukemia

N. Kröger, A. Zander, U. Bacher, 2009, Bone Marrow Transplantation.

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)

J. Panse, N. Kröger, D. Atanackovic, 2006, Bone Marrow Transplantation.

Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

N. Kröger, J. Sierra, D. Niederwieser, 2002, British journal of haematology.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.

C. Bokemeyer, T. Stahl, N. Kröger, 2010, Experimental hematology.

Comparison of the Efficacy of TAD-TAD and “7+3” Regimens in Adult AML, the Role of Dose Intensity and Mdr-1 Gene Expression

E. Kuchinskaya, A. Zaritskey, T. Zabelina, 2001 .

Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

J. Panse, N. Kröger, A. Zander, 2005, British journal of haematology.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

N. Kröger, A. Zander, M. Binder, 2013, Annals of Hematology.

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004

N. Kröger, A. Zander, G. Ehninger, 2009, Annals of Hematology.

Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis

N. Kröger, C. Wolschke, F. Ayuk, 2018, British journal of haematology.

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.

N. Kröger, C. Wolschke, F. Ayuk, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation

N. Kröger, A. Zander, A. Hinke, 2006, Bone Marrow Transplantation.

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)

N. Schmitz, H. Einsele, N. Kröger, 2003, Bone Marrow Transplantation.

Glucagon like peptide-2 for Intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.

M. Boerries, T. Clauditz, T. Brummer, 2020, Blood.

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up

N. Kröger, A. Zander, B. Fehse, 2006, Bone Marrow Transplantation.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis

T. Stahl, N. Kröger, A. Zander, 2010, Leukemia & lymphoma.

Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors

N. Kröger, A. Zander, F. Ayuk, 2009, Leukemia & lymphoma.

Lenalidomide after Allogeneic Stem Cell Transplantation in Multiple Myeloma.

A. Zander, D. Blaise, M. Mohty, 2007 .

Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma

N. Kröger, A. Zander, W. Krüger, 2001, British journal of haematology.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.

N. Kröger, D. Atanackovic, A. Zander, 2006, Experimental hematology.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

N. Kröger, A. Zander, R. Brand, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total Marrow Irradiation (TMI), Busulfan, and Cyclophosphamide for Allografting in Multiple Myeloma. A Pilot Study

H. Einsele, N. Kröger, A. Zander, 2003 .

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors

N. Kröger, A. Zander, W. Krüger, 2002, Bone Marrow Transplantation.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.

N. Kröger, P. Dreger, T. D. de Witte, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.

W. Siegert, N. Kröger, A. Zander, 2002, Haematologica.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2009, Experimental hematology.

Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.

N. Kröger, A. Zander, B. Fehse, 2006, Experimental hematology.

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.

H. Einsele, N. Kröger, A. Zander, 2004, Blood.

Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation.

N. Kröger, A. Zander, B. Fehse, 2003, Journal of hematotherapy & stem cell research.

Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors

N. Klein, B. Fehse, R. Thiébaut, 2010, Bone Marrow Transplantation.

Caspofungin as secondary prophylaxis or therapy in patients undergoing allogeneic stem cell transplantation with a prior or ongoing history of systemic or invasive fungal infections

J. Panse, N. Kröger, A. Zander, 2008 .

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

Y. Hildebrandt, N. Kröger, K. Pflüger, 2013, Bone Marrow Transplantation.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. Miguel, C. Bokemeyer, N. Kröger, 2008, Leukemia.

Proliferation and maturation of hemopoietic cells in adult patients with different forms of acute leukemia and chronic myeloid leukemia in agar and liquid cultures.

T. Zabelina, E. Elstner, B. Afanasiev, 1981, Haematology and blood transfusion.

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T‐cell depletion with anti‐thymocyte globulin

A. Zander, A. Hinke, W. Krüger, 2001, British journal of haematology.

Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia

N. Kröger, A. Zander, F. Ayuk, 2009, Acta Haematologica.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. San Miguel, J. Miguel, C. Bokemeyer, 2008, Leukemia.

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML

N. Kröger, I. Moiseev, B. Afanasyev, 2021, Bone Marrow Transplantation.

ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)

N. Kröger, G. Ehninger, M. Bornhäuser, 2003, Bone Marrow Transplantation.

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT

A. Zander, F. Ayuk, R. Erttmann, 2008, Bone Marrow Transplantation.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation

H. Rohde, A. Bacher, N. Kröger, 2015, Acta Haematologica.

Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

H. Einsele, A. Zander, A. Nagler, 2007 .

Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation

N. Kröger, A. Hansen, B. Eifrig, 2003, Bone Marrow Transplantation.

Anti-Thymocyte-Globulin as part of the preparative regimen prevents graft failure and severe Graft versus Host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors

N. Kröger, A. Zander, M. Dürken, 2001, Annals of Hematology.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.

R. Porcher, N. Kröger, M. Robin, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dose‐reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia

N. Kröger, A. Hansen, U. Kordes, 2002, British journal of haematology.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation

N. Kröger, A. Zander, U. Pein, 2014, Bone Marrow Transplantation.

CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.

N. Kröger, T. Klingebiel, B. Fehse, 2006, Cytotherapy.

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia

N. Kröger, W. Fiedler, A. Zander, 2000, Bone Marrow Transplantation.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

N. Kröger, A. Zander, A. Nagler, 2004, Blood.

After major ABO‐mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B

W. Siegert, N. Kröger, G. Ehninger, 2005, Transfusion.

Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis

N. Kröger, F. Ayuk, T. Zabelina, 2016, Bone Marrow Transplantation.

Stem Cell Transplantation in Acute Myeloid Leukemia after Conditioning with Busulfan, Cyclophosphamide and Different Dosages of Etoposide (VP-16)

N. Kröger, W. Fiedler, A. Zander, 2003 .

N. Schmitz, N. Kröger, A. Zander, 2002, Blood.

Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.

N. Kröger, A. Zander, B. Fehse, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor choice according to age for allo-SCT for AML in complete remission

N. Kröger, A. Zander, F. Ayuk, 2013, Bone Marrow Transplantation.

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

W. Siegert, N. Kröger, W. Krüger, 2001, Bone Marrow Transplantation.

Second Allogeneic Stem Cell Transplantation in Myeloid Malignancies

N. Kröger, A. Zander, M. Hartwig, 2009, Acta Haematologica.

Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis

W. Siegert, N. Kröger, A. Zander, 2004, Bone Marrow Transplantation.

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.

N. Kröger, A. Zander, B. Fehse, 2009, Experimental hematology.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.

N. Kröger, H. Kreipe, J. Thiele, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years

N. Kröger, C. Wolschke, F. Ayuk, 2019, European journal of haematology.

Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT)

N. Kröger, M. Bornhäuser, W. Bethge, 2019, Transfusion Medicine and Hemotherapy.

Anti Thymocyte Globuline Allows for Successful Transplantation from HLA Mismatched Unrelated Donors

N. Kröger, A. Zander, B. Fehse, 2008 .

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

N. Kröger, S. Iacobelli, A. Zander, 2005, British journal of haematology.

Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells.

N. Kröger, A. Zander, B. Fehse, 2004, Blood.

Postallogeneic monitoring with molecular markers detected by pretransplant next‐generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms

A. Kohlmann, T. Haferlach, N. Kröger, 2014, European journal of haematology.

with multiple myeloma immunotherapy after allogeneic stem cell transplantation in patients Low-dose thalidomide and donor lymphocyte infusion as adoptive

N. Kröger, A. Zander, A. Nagler, 2013 .

Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia

N. Kröger, A. Zander, F. Ayuk, 2010, Acta Haematologica.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.

M. Heuser, F. Thol, A. Ganser, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

M. Cazzola, H. Deeg, N. Kröger, 2015, Blood.

Bone Marrow Transplantation from Mismatched Unrelated Donors

N. Kröger, A. Zander, W. Krüger, 2003 .

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Y. Hildebrandt, N. Kröger, A. Zander, 2010, Blood.

Evaluation of BM cytomorphology after allo-SCT in patients with AML

T. Haferlach, C. Bokemeyer, N. Kröger, 2012, Bone Marrow Transplantation.

Ruxolitinib As Pretreatment Before Allogeneic Stem Cell Transplantation For Myelofibrosis

G. Wulf, D. Wolf, F. Ayuk, 2013 .

Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT

N. Kröger, A. Zander, U. Bacher, 2012, Bone Marrow Transplantation.

Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease

N. Kröger, F. Ayuk, C. Wolschke, 2016 .

Correlation of somatic mutations with outcome after FLAMSA‐busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes

N. Kröger, M. Alawi, C. Wolschke, 2016, European journal of haematology.

N. Kröger, B. Fehse, C. Wolschke, 2016, Bone Marrow Transplantation.

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

S. Iacobelli, A. Nagler, K. Peggs, 2004 .

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML

T. Haferlach, C. Bokemeyer, C. Horn, 2013, Bone Marrow Transplantation.

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

T. Haferlach, C. Bokemeyer, C. Horn, 2012 .

Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny

M. Aepfelbacher, A. Bacher, N. Kröger, 2010, Leukemia & lymphoma.

Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin

N. Kröger, W. Krüger, U. Kordes, 2002, Annals of Hematology.

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

N. Kröger, A. Zander, R. Brand, 2011 .

Post-Allogeneic Monitoring with Molecular Markers Detected by Pre-Transplant Next Generation Sequencing (NGS) Predicts Clinical Relapse in Patients with Chronic Myelomonocytic Leukemia (CMML)

A. Kohlmann, T. Haferlach, N. Kröger, 2012 .

Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis

B. Fehse, F. Henes, F. Ayuk, 2023, Bone Marrow Transplantation.

N. Schmitz, N. Kröger, A. Zander, 2002, Blood.

Induction Chemotherapy Followed Immediately by Busulfan-Based Reduced Conditioning and Allografting in Elderly Patients with Advanced MDS or sAML.

N. Kröger, A. Zander, B. Fehse, 2009 .

Bull's neck in Hodgkin's disease: a CT imaging appraisal.

C. Thiede, M. Bornhäuser, J. Schetelig, 1996 .